KeyBanc Starts Cantel Medical (CMD) at Sector Weight

KeyBanc analyst Matthew Mishan initiates coverage on Cantel Medical (NYSE: CMD) with a Sector Weight rating.

The analyst comments "Despite a positive LT bias, we do not see an obvious catalyst to reinvigorate CMD's momentum as it works through various NT headwinds to its more-typical above-market organic revenue and EPS growth. More specifically: 1) it has an attractive mix of leading infection prevention products; 2) there has been a NT pause to its 8-10% growth outlook, and it’s too early to have confidence in a FY20 reset; 3) we are encouraged an ERP implementation could eventually enable greater margin expansion and larger M&A; and 4) risk/reward appears balanced."

For an analyst ratings summary and ratings history on Cantel Medical click here. For more ratings news on Cantel Medical click here.

Shares of Cantel Medical closed at $80.96 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• KeyBanc Reiterates Underweight Rating on Apple (AAPL)
• New Street Research Upgrades Micron Technology (MU) to Buy